By turn, the presence of CYP3A activity would confer to cancer cells the ability to inactivate two widely used taxanes, such as paclitaxel and docetaxel and vinca alkaloids that are CYP3A4 substrates (Guengerich, 1999; Yao et al, 2000). This evidence concerns the gene CYP3A4 and cancer.